Zapping resistant tumors: could radiation extend the life of current breast cancer therapy?
NCT ID NCT06882499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their current treatment longer, compared to switching to a different systemic therapy chosen by their doctor. The study aims to see if this strategy delays the need for a treatment change.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative radiotherapy (SABR)
What this could lead to
If successful, this approach could allow patients to stay on their current hormone therapy longer by zapping resistant spots with radiation, delaying the need for stronger drugs.
What could go wrong
This is a small, early-stage trial (74 participants) and may not show a clear benefit. SABR can cause side effects like fatigue or local pain, and not all patients may be suitable for radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••